Sangamo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 405
- Market Cap
- $170.2M
- Introduction
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology pl...
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT05987527
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇬🇧Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
- Conditions
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT05145062
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Long-Term Follow-up of Subjects Who Were Treated With ST-920
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT05039866
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT04817774
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇬🇧Oxford University Hospitals NHS Foundation Trust,, Oxford, United Kingdom
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04628871
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸New York University Grossman School of Medicine, New York, New York, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 38
- Registration Number
- NCT04201782
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
🇺🇸Circle CARE Center, LLC, Norwalk, Connecticut, United States
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT04046224
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇮🇹Azienda Ospedaliero-Universitaria Careggi, Florence, Tuscany, Italy
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03653247
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Investigational Site Number 101, Bethesda, Maryland, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT03432364
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT03041324
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸NYU School of Medicine, Neurogenetics Division, New York, New York, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States